Cadila Pharma launches Hyperacidity drug Esomeprazole under brand name Esiloc in India
In an endeavor to improve the treatment options available for hyperacidity & drug induced Gastritis, Esiloc™ will be 50% more economical, thus making it a superior yet affordable choice.
Ahmedabad: Ahmedabad-based Cadila Pharmaceuticals Limited has announced the launch of Esomeprazole tablets for the treatment of Hyperacidity & Drug Induced Gastritis under the brand name Esiloc™.
In an endeavor to improve the treatment options available for hyperacidity & drug induced Gastritis, Esiloc™ will be 50% more economical, thus making it a superior yet affordable choice. Esiloc™ will be made available in 20 mg and 40 mg tablets.
Esomeprazole which is a proton pump inhibitor (PPI*), acts on the luminal surface of gastric parietal cells, resulting in inhibition of acid secretion. Esomeprazole provides higher rates of healing of erosive GERD and sustained resolution of heartburn in patients.
Gastro-oesophageal reflux (GERD) is reflux of gastric contents into the oesophagus. Heart burn is a very common symptom of GERD. GERD is often overseen and if untreated, can lead to conditions like peptic ulcer, chest pain, esophagus cancer & other fatal conditions.
Read also: Cadila Pharma unveils antihistamine drug Bilastine in India
Cadila Pharmaceuticals Ltd. has recently concluded and cleared USFDA inspection successfully in February 2020.
Cadila Pharmaceuticals is a multinational research-based pharmaceutical group in India with more than 6 decades of experience.
Read also: Cadila Pharma launches immunity booster syrup under brand name
